YUSUF HAMIED

Cipla Signed Licensing Pact with Gilead to Manufacture & Distribute Remdesivir

The agreement is part of Cipla's efforts to enhance global access to life-saving treatments for patients affected by the pandemic. Cipla will be permitted to manufacture the active pharma ingredient (API) and finished product and market it in 127 countries including India and South Africa under Cipla's own brand name.